I am with Hawk - next quarterly would be fundamental in some long term holders making decisions. The company at .10c was very interesting - FDA approval was just received and they spruiked the FFN / Hologic deals like no tomorrow as well as the US market. The US market will initially be determined on the next quarterly given the "full flu season" as Paul and Doug keep reiterating. Removing the CLIA requirement etc and late PLA reimbursement, they have further distributor partners since last years $700,000 quarter. If this "flu season" quarter is a lot bigger than last year, the SP should be north of where it is current floundering.
Add to My Watchlist
What is My Watchlist?
